NCT05763277
Ate-Bev Early Response Prediction Model in Advanced HCC
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 31, 2025 to Dec 31, 2027
- Eligibility criteria expanded, about 4 words
- Study completion pushed from Dec 31, 2026 to Dec 31, 2028
- Notable Primary completion date: May 22, 2024 to Dec 31, 2025
- Study completion date: May 22, 2025 to Dec 31, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
progression free survival
Timeframe: the follow up will be continued until June 22th 2025.
Secondary (1)
Overall survival
Arms and interventions
Ate-Bev
Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded.
Diagnostic tests: Early response evaluation
Sites
1 site in 1 country
- Seoul National University HospitalSeoul, South Korea